Form 4: Evoke Pharma Director's Options Convert Post-Merger

Evoke Pharma director Greg Pyszczymuka's stock options were canceled and converted to cash following the company's merger with QOL Medical, LLC.

Summary

• Evoke Pharma Inc. completed a merger with QOL Medical, LLC's wholly-owned subsidiary, QOL-EOS Merger Sub, Inc., effective December 17, 2025.
• As a result of the merger, Evoke Pharma Inc. is now a wholly-owned subsidiary of QOL Medical, LLC.
• Director Greg Pyszczymuka's outstanding stock options were accelerated, fully vested, canceled, and converted into a cash payment immediately prior to the merger's effective time.
• The cash payment for each option was calculated as the aggregate number of shares underlying the option multiplied by the difference between $11.00 and the option's per share exercise price.
• Options converted included 5,833 shares with an exercise price of $5.26 and 1,155 shares with an exercise price of $3.453.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger and the conversion of director options into cash, indicating a positive outcome for option holders and the finalization of a strategic transaction.

Positives

• The merger successfully closed, indicating a strategic transaction for Evoke Pharma.
• Director Greg Pyszczymuka's stock options were accelerated and fully vested, ensuring a cash payout for his equity incentives.
• Option holders received a cash payment based on an implied merger price of $11.00 per share, less their exercise price.

Negatives

• Evoke Pharma Inc. is no longer an independent publicly traded company, becoming a wholly-owned subsidiary.
• Public shareholders would have received cash for their shares, and the company's stock will no longer trade on public exchanges.

Risks

• The filing does not detail future risks for the now-private entity, as it primarily reports a past transaction for a director.

Future Outlook

Evoke Pharma Inc. is no longer an independent public entity; it now operates as a wholly-owned subsidiary of QOL Medical, LLC. The future outlook for the former public company is that it has been integrated into its parent company's operations.

Industry Context

The merger of Evoke Pharma Inc. into QOL Medical, LLC reflects a common trend in the pharmaceutical and biotech industries where smaller companies are acquired by larger entities for strategic reasons, such as pipeline assets, market access, or consolidation. This transaction integrates Evoke Pharma's assets and operations under the QOL Medical umbrella.

Comparison to Industry Standards

• The conversion of stock options into cash at a predetermined merger price is a standard practice in corporate acquisitions, ensuring that equity incentive holders receive value for their vested options.
• The implied merger price of $11.00 per share would typically be evaluated against the company's historical trading performance and valuations of comparable acquisitions in the biotech sector, though this filing does not provide sufficient detail for such a comparative analysis.

Corporate Governance

Related Party Transactions

• The conversion of director Greg Pyszczymuka's stock options into cash is a direct result of the Merger Agreement between Evoke Pharma Inc. and QOL Medical, LLC.

Stakeholder Impact

• Shareholders: Public shareholders of Evoke Pharma Inc. would have received cash for their shares as part of the merger consideration (implied $11.00 per share).
• Employees: Evoke Pharma employees are now part of the QOL Medical, LLC organization.
• Option Holders: Holders of Evoke Pharma stock options, including Director Greg Pyszczymuka, received cash payouts for their vested options.

Next Steps

• For the reporting person, the transaction related to these specific options is complete.
• Evoke Pharma Inc. will continue operations as a private, wholly-owned subsidiary of QOL Medical, LLC.

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, Merger, Acquisition, Stock Options, Form 4, Beneficial Ownership, Corporate Governance